Drug

Zimberelimab

Late-stage clinical development

ClassProgrammed cell death protein 1 inhibitor

Also known as Immunoglobulin g4(231-proline), anti-(human programmed cell death protein 1) (human monoclonal ab122 .gamma.4-chain), disulfide with human monoclonal ab122 .lambda.-chain, dimer.

RxNorm2615290 ChEMBLCHEMBL4297856UNIIZBL7O904IL

Research papers

Active clinical trials

Programmed cell death protein 1

Primary target

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Phase 1 Study to Evaluate the Safety and Tolerability of GS-4528 as Monotherapy and in Combination With an Anti-PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors

Clinical trial2026-10-31Primary completion · ClinicalTrials.gov

A Pilot Study to Evaluate the Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer

Clinical trial2026-10-31Primary completion · ClinicalTrials.gov

A Phase 2 Trial to Evaluate the Safety and Efficacy of Combination Therapies in Patients With Advanced Upper Gastrointestinal Tract Malignancies (EDGE-Gastric)

Clinical trial2026-10-26Status changed to Completed · ClinicalTrials.gov

An Open Label, Single-arm, Phase 2 Study of Perioperative Sacituzumab Govitecan in Combination With Zimberelimab and Domvanalimab for Patients With Muscle Invasive Bladder Cancer Ineligible for Cisplatin-based Chemotherapy

Clinical trial2026-10-07Results expected Q1 2030 · ClinicalTrials.gov

A Phase 1 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Denikitug (GS-1811), an Afucosylated Anti-CCR8 Monoclonal Antibody, as Monotherapy and in Combination With an Anti-PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors

Clinical trial2026-09-17Status changed to Active, not recruiting · ClinicalTrials.gov

A Phase 1 Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants With Gastrointestinal Malignancies

Clinical trial2026-09-09Status changed to Completed · ClinicalTrials.gov

A Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Participants With Previously Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma

Clinical trial2026-09-03Status changed to Completed · ClinicalTrials.gov

A Phase 1, Open-label, Dose Escalation and Dose Expansion Study, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521 Monotherapy and Combination Therapies in Participants With Clear Cell Renal Cell Carcinoma and Other Solid Tumors

Clinical trial2026-08-31Results expected Q1 2029 · ClinicalTrials.gov

A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants With Advanced Malignancies

Clinical trial2026-08-31Results expected Q3 2027 · ClinicalTrials.gov

Official Title: A Phase 2 Study to Evaluate Zimberelimab (AB122) Combined With AB154 in Front-Line, PD-L1-High, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Clinical trial2026-08-31Results expected Q2 2027 · ClinicalTrials.gov

VELOCITY-HNSCC Substudy-01: A Phase 2 Study of Novel Combination Therapies in Participants With Previously Untreated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status

Clinical trial2026-08-31Primary completion · ClinicalTrials.gov

Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II study.

Research2023-12-04International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Zimberelimab

Aliases & brands

Immunoglobulin g4(231-proline), anti-(human programmed cell death protein 1) (human monoclonal ab122 .gamma.4-chain), disulfide with human monoclonal ab122 .lambda.-chain, dimer

RxNorm CUI

2615290

ChEMBL ID

CHEMBL4297856

UNII

ZBL7O904IL

Primary mechanism

Programmed cell death protein 1 inhibitor